A Phase I Study of TAK-228 (MLN0128) in Combination With Carboplatin Plus Paclitaxel in Patients With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 16 Mar 2018
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Sapanisertib (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions
- 12 Mar 2018 Planned End Date changed from 1 Apr 2024 to 1 Mar 2024.
- 12 Mar 2018 Planned primary completion date changed from 1 Apr 2023 to 1 Mar 2023.
- 12 Mar 2018 Status changed from not yet recruiting to recruiting.